These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18816151)

  • 1. Effect of hyperprolactinemia during development in children and adolescents.
    Correll CU
    J Clin Psychiatry; 2008 Aug; 69(8):e24. PubMed ID: 18816151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects.
    Roke Y; van Harten PN; Boot AM; Buitelaar JK
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):403-14. PubMed ID: 19702492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone-induced hyperprolactinemia in adolescents: A case series.
    Madhusoodanan S; Moise D
    J Clin Psychiatry; 2006 Jul; 67(7):1110-3. PubMed ID: 16889455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management of Antipsychotic-Induced Hyperprolactinemia.
    Wong-Anuchit C
    Perspect Psychiatr Care; 2016 Apr; 52(2):145-52. PubMed ID: 25772527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
    Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
    Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L; Eap CB
    J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
    Keller R; Mongini F
    Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary gamma-aminobutyric acid receptor stimulation by carnitine may be a new strategy for antipsychotic-induced hyperprolactinemia.
    Nakamura M; Nagamine T
    Psychiatry Clin Neurosci; 2017 Aug; 71(8):571-572. PubMed ID: 28569425
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyperprolactinemia in mentally ill patients].
    Carvalho MM; Góis C
    Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Female puberty: clinical implications for the use of prolactin-modulating psychotropics.
    Becker AL; Epperson CN
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):207-20. PubMed ID: 16321731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
    Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
    Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders.
    Takechi K; Yoshioka Y; Kawazoe H; Tanaka M; Takatori S; Kobayashi M; Matsuoka I; Yanagawa H; Zamami Y; Imanishi M; Ishizawa K; Tanaka A; Araki H
    Biol Pharm Bull; 2017; 40(10):1775-1778. PubMed ID: 28966250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?
    Smith S
    J Reprod Med; 1992 Aug; 37(8):737-40. PubMed ID: 1359137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of psychotropic-induced hyperprolactinemia.
    Marken PA; Haykal RF; Fisher JN
    Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
    Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
    J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents.
    Saito E; Correll CU; Gallelli K; McMeniman M; Parikh UH; Malhotra AK; Kafantaris V
    J Child Adolesc Psychopharmacol; 2004; 14(3):350-8. PubMed ID: 15650492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.